(Q33361578)

26 July 2017

title

The future of patient-derived tumor xenografts in cancer treatment (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Augusto Villanueva

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

author name string

Daniela Sia

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

Ismail Labgaa

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

publication date

24 September 2015

1 reference

26 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

issue

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

page(s)

1671-1683

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

Assumptions of expected benefits in randomized phase III trials evaluating systemic treatments for cancer

3 June 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Cancer cell lines for drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Do cell lines in vitro reflect the properties of the tumours of origin? A study of lines derived from human melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Genetically engineered mouse models: future tools to predict clinical trial results in oncology?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Contributions of human tumor xenografts to anticancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Human gastric choriocarcinoma serially transplanted in nude mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Transplantation of Human Tumors in Nude Mice23

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived tumour xenografts as models for oncology drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment of human tumor xenografts in immunodeficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived tumor xenografts: transforming clinical samples into mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Development and characterization of efficient xenograft models for benign and malignant human prostate tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Direct in vivo xenograft tumor model for predicting chemotherapeutic drug response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A novel animal model for locally advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment of a patient-derived Wilms' tumor xenograft model: a promising tool for individualized cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment and characterisation of a new breast cancer xenograft obtained from a woman carrying a germline BRCA2 mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Development and characterization of clinically relevant tumor models from patients with renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived xenografts of non-small-cell lung cancer: a pre-clinical model to evaluate adjuvant chemotherapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

In vivo imaging enables high resolution preclinical trials on patients' leukemia cells growing in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Histological and molecular evaluation of patient-derived colorectal cancer explants

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment of human colon cancer cell lines from fresh tumors versus xenografts: comparison of success rate and cell line features

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Lung cancer xenografting alters microRNA profile but not immunophenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Genome remodelling in a basal-like breast cancer metastasis and xenograft

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Molecular profiling of patient-derived breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived xenograft models: an emerging platform for translational cancer research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Systemic human T cell developmental processes in humanized mice cotransplanted with human fetal thymus/liver tissue and hematopoietic stem cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Murine models to evaluate novel and conventional therapeutic strategies for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Humanized mouse model of ovarian cancer recapitulates patient solid tumor progression, ascites formation, and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Humanized mice for immune system investigation: progress, promise and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Overcoming current limitations in humanized mouse research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Phenotypic characterization of human colorectal cancer stem cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived luminal breast cancer xenografts retain hormone receptor heterogeneity and help define unique estrogen-dependent gene signatures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Distinct choline metabolic profiles are associated with differences in gene expression for basal-like and luminal-like breast cancer xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Establishment and characterization of a panel of human uveal melanoma xenografts derived from primary and/or metastatic tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Activity of docetaxel with or without estramustine phosphate versus mitoxantrone in androgen dependent and independent human prostate cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Inhibiting aurora kinases reduces tumor growth and suppresses tumor recurrence after chemotherapy in patient-derived triple-negative breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Identification of cells initiating human melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

An integrin β₃-KRAS-RalB complex drives tumour stemness and resistance to EGFR inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Sensitization of pancreatic cancer stem cells to gemcitabine by Chk1 inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Trastuzumab anti-tumor efficacy in patient-derived esophageal squamous cell carcinoma xenograft (PDECX) mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Inhibition of angiogenic and non-angiogenic targets by sorafenib in renal cell carcinoma (RCC) in a RCC xenograft model

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Translating the therapeutic potential of AZD4547 in FGFR1-amplified non-small cell lung cancer through the use of patient-derived tumor xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Tumor grafts derived from women with breast cancer authentically reflect tumor pathology, growth, metastasis and disease outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Antitumor effects and biomarkers of activity of AZD0530, a Src inhibitor, in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

The anti-CD19 antibody-drug conjugate SAR3419 prevents hematolymphoid relapse postinduction therapy in preclinical models of pediatric acute lymphoblastic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Personalized medicine and pharmacogenetic biomarkers: progress in molecular oncology testing

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Genomics-driven oncology: framework for an emerging paradigm

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

New cast for a new era: preclinical cancer drug development revisited.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A co-clinical platform to accelerate cancer treatment optimization.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

The APL paradigm and the "co-clinical trial" project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Integrated preclinical and clinical development of mTOR inhibitors in pancreatic cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

One mouse, one patient paradigm: New avatars of personalized cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Priceless GEMMs: genetically engineered mouse models for colorectal cancer drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A pilot clinical study of treatment guided by personalized tumorgrafts in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Low-molecular contrast agent dynamic contrast-enhanced (DCE)-MRI and diffusion-weighted (DW)-MRI in early assessment of bevacizumab treatment in breast cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Metabolic biomarkers for response to PI3K inhibition in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

A model for personalized in vivo analysis of human immune responsiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Stability of gene expression and epigenetic profiles highlights the utility of patient-derived paediatric acute lymphoblastic leukaemia xenografts for investigating molecular mechanisms of drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Circulating tumor cells as a biomarker of response to treatment in patient-derived xenograft mouse models of pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

Organoid models of human and mouse ductal pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.15.102

21 January 2018

Identifiers

DOI

10.2217/PGS.15.102

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26402657%20AND%20SRC:MED&resulttype=core&format=json

3 June 2020

1 reference